Sun Pharma Q3 FY26 Results Out! Pharma giant net profit rises 16%; Rs 11 dividend announced – Check record date

Sun Pharmaceutical Industries Ltd on Friday reported its consolidated financial results for the third quarter ended December 31, 2025, and announced an interim dividend for the financial year 2025-26.

The company said its board of directors has declared an interim dividend of Rs 11 per equity share of face value Rs 1 each for FY26. The record date for determining shareholder eligibility for the interim dividend has been fixed as February 5, 2026.

The interim dividend will be paid on or before February 16, 2026. In the previous financial year, the company had declared an interim dividend of Rs 10.50 per share.

The results were taken on record by the board of directors at a meeting held on Friday.

For the quarter ended December 31, 2025, Sun Pharmaceutical Industries reported consolidated sales of Rs 15,469 crore, registering a year-on-year growth of 15.1 per cent.

Earnings before interest, tax, depreciation and amortisation for the quarter stood at Rs 4,949 crore, up 23.4 per cent from the corresponding period last year. The EBITDA margin for the quarter was reported at 31.9 per cent.

Profit before exceptional items and tax during the quarter rose 24.4 per cent to Rs 4,717 crore. Net profit for the quarter increased 16 per cent to Rs 3,369 crore. The company’s research and development expenditure during the quarter stood at Rs 893 crore, accounting for 5.8 per cent of sales.

Global Innovative Medicines sales during the quarter stood at US$ 423 million. This included a milestone payment of US$ 55 million. Excluding the milestone income, Global Innovative Medicines sales rose 13.2 per cent year-on-year and accounted for 21.2 per cent of total sales during the quarter.

For the nine months ended December 31, 2025, consolidated sales stood at Rs 43,660 crore, marking a growth of 11.3 per cent over the same period last year. EBITDA for the nine-month period rose 19.2 per cent to Rs 13,777 crore, while the EBITDA margin stood at 31.4 per cent.

Profit before exceptional items and tax for the nine months increased 19.1 per cent to Rs 12,875 crore. Net profit for the period stood at Rs 8,765 crore. Research and development investment during the nine months was reported at Rs 2,578 crore, representing 5.9 per cent of sales.

India formulation sales during the December quarter were reported at Rs 4,999 crore, registering a growth of 16.2 per cent compared with the same quarter last year. India formulation sales accounted for 32.3 per cent of total consolidated sales. For the nine months, India formulation sales stood at Rs 14,455 crore, up 13.7 per cent year-on-year.

The company said it continues to be the largest pharmaceutical company in India. Its market share increased from 8.1 per cent to 8.4 per cent, as per the Pharmarack MAT December 2025 report. As per the SMSRC report for the July to October 2025 period, the company held the top position by prescriptions in 14 doctor categories.

Formulation sales in the United States stood at US$ 477 million during the December quarter, marginally higher by 0.6 per cent. Sales from the US accounted for around 27.5 per cent of total consolidated sales. For the nine months, formulation sales in the US were reported at US$ 1,445 million.

Emerging markets formulation sales during the quarter were reported at US$ 337 million, registering a growth of 21.6 per cent year-on-year. Emerging markets accounted for 19.4 per cent of total consolidated sales. For the nine months, emerging markets formulation sales stood at US$ 960 million, growing 12.4 per cent over the same period last year.

Formulation sales in the rest of the world markets stood at US$ 296 million during the quarter, up 14.5 per cent year-on-year, and accounted for 17.1 per cent of total consolidated sales. For the nine months, the rest of the world formulation sales were reported at US$ 749 million, registering a growth of 15.8 per cent.

External sales of active pharmaceutical ingredients during the December quarter stood at Rs 541 crore, lower by 4.7 per cent compared with the same period last year. For the nine months, API sales were reported at Rs 1,511 crore, down 5.3 per cent year-on-year.